ArticleFrontiers in immunology2026
Case Report: Neurexin-3α-associated autoimmune encephalitis with co-existence of possible anti-MOG-associated involvement.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune encephalitis (AE) associated with neurexin-3α antibodies is a rarely reported disorder that commonly presents with severe neuropsychiatric manifestations. Case presentation: We report a patient who tested positive for neurexin-3α and myelin oligodendrocyte glycoprotein (MOG) antibodies at low titers. The patient presented with seizures, mental and behavioral disturbances, and cognitive impairment. Brain MRI showed increased signal intensity in the bilateral hippocampus and leptomeningeal enhancement in the left cerebral hemisphere. Serum cell-based assay findings, confirmed by tissue-based assay, were positive for neurexin-3α antibodies. The patient was diagnosed with anti-neurexin-3α encephalitis, with possible concurrent anti-MOG-associated involvement. Clinical symptoms improved after treatment with glucocorticosteroids and intravenous immunoglobulin. Conclusion: Although overlapping antibodies in AE are relatively common, the co-occurrence of neurexin-3α and MOG antibodies has not been previously reported. This case provides new insights into the diagnosis and treatment of neurexin-3α-associated AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.